Original Research Article

Morphological spectrum of salivary gland tumors with special reference to mucin stains

Faeeza Begum1,*, Shaista Choudhary1

1Dept. of Pathology, Dr. B R Ambedkar Medical College, Bangalore, Karnataka, India

A R T I C L E  I N F O

Article history:
Received 20-09-2021
Accepted 21-10-2021
Available online 26-11-2021

Keywords:
Salivary gland
Benign
Malignant
Pleomorphic adenoma
Mucin
Mucoepidermoid carcinoma

A B S T R A C T

Background: Salivary gland neoplasms are rare and constitute about 3% of all head and neck neoplasms. Mucins are altered in pathological states and are stained by special stains like Periodic Acid Schiff, Alcian Blue and Mucicarmine.

Objectives: To study the histomorphology of resected salivary gland tumors and mucin staining pattern wherever indicated.

Materials and Methods: Surgically resected specimens received at our tertiary care hospital and subjected to histopathological examination. Specimens were fixed in 10% formalin, processed and embedded in paraffin blocks, serially cut to get sections of 3-5 microns thickness. Stained with hematoxylin and eosin for all. Mucin stains were used wherever applicable.

Results: Total number of cases studied were 70. Out of which 46 were benign (65.7%) and 24 were malignant (34.3%). Among benign tumours, Pleomorphic adenoma was the commonest tumour (48.57), followed by Warthin tumor (7.14%), Basal cell adenoma (4.28%), Myoepithelioma (1.43%), Oncocytoma (1.43%), Hemangioma (1.43%), Sailolipoma (1.43%). The Mucoepidermoid carcinoma was the most common malignant tumor (17.14%) followed by Adenoid cystic carcinoma (5.71%), Acinic cell carcinoma (4.28%), Polymorphous adenocarcinoma (1.43%), Epithelial myoepithelial carcinoma, Squamous cell carcinoma (1.43%), Salivoblastoma (1.43%), Lymphoma (1.43%). Parotid was most common site for both benign and malignant tumor. Females are affected more commonly than males. Mucin staining pattern was noted.

Conclusion: Salivary gland tumors have complex range of morphological spectrum. Histopathological examination is the golden standard for diagnosis and mucin stain would add as an adjunct to the diagnosis.

This is an Open Access (OA) journal, and articles are distributed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike 4.0 License, which allows others to remix, tweak, and build upon the work non-commercially, as long as appropriate credit is given and the new creations are licensed under the identical terms.

For reprints contact: reprint@ipinnovative.com

1. Introduction

Salivary glands are distinctive amongst the secretory glands, with most heterogeneous group of tumors, exhibiting complex and wide histological diversity. These are exocrine in nature categorized into major and minor salivary glands. Tumors arising from salivary glands, constitute approximately 1% of all neoplasms in the body and 3–6% of all head and neck tumors with an estimated worldwide incidence of 0.4–13.5 per 1,00,000 population. About 70 -80% of tumors arise from parotid gland, 7-10% are located in submandibular gland, the remaining are in sublingual and other minor salivary glands. Tumors that arises from parotid, only 15-30% are malignant. More than 50% of those arising in the submandibular or sublingual glands are malignant.

Salivary glands are tubuloacinar exocrine organs responsible for production of saliva. Mucins are main component of saliva composed of complex carbohydrates with sugar moieties and amino acids.
Glandular secretions protect the mucosa of the oral cavity which are mainly serous and mucinous in nature rich in mucosubstances. Any change in mucin pattern may induce disease or malignant process. Mucin can be categorized into acidic (sulphomucin and sialomucins) and neutral mucins stained by various methods such as periodic acid schiff (PAS), mucicarmine, alcian blue (AB) and in combination.

Hematoxylin and Eosin (H&E) is considered to be the gold standard in diagnosis of salivary gland tumors. Most patients with benign tumors present with painless swelling of the gland involved. Neurological signs, such as numbness or weakness caused by nerve involvement, indicate a malignancy. The prognosis is most favorable when the tumor is located in the parotid gland, followed by submandibular gland, the least favorable sites are the sublingual and minor salivary glands.

2. Material and Methods

It is a Prospective observational study. Salivary gland specimen received at Department of pathology, done at our tertiary care center between November 2018 to June 2021 were taken for the study. Ethical committee clearance was obtained before the study.

2.1. Inclusion criteria

All benign and malignant salivary gland tumors.

2.2. Exclusion criteria

All autolytic samples. Inflammatory, infective and miscellaneous condition.

Salivary gland specimens were obtained after written and informed consent. Details of clinical data and investigations performed collected for available cases from histopathological requisition form. All specimen were fixed in 10% Formalin for a period of 10 – 12 hours. Specimens gross and cut surface examined for size, shape, color, circumscribed or infiltrative borders and presence of cystic changes were noted. The sections were taken from the lesion, its margins, surrounding tissues.

Tissues were processed, embedded in paraffin and sections were cut at 3-5 microns thick and were stained with Haematoxylin and Eosin. Selected cases special stains like Periodic acid Schiff (PAS), Alcian blue (AB) and Mucicarmine (MC) stain were also done, slides were examined. The details of cellular pattern, encapsulation, perineural and vascular invasion with mucin staining pattern was observed. The tumors were studied according to World Health Organization’s histologic typing of salivary gland tumors 4th edition.

3. Results

Of the total 70 cases (Table1), of which 46 cases were benign and 24 cases were malignant (chart1).

![Total Cases Chart](chart1)

Chart 1: Showing distribution of salivary gland lesions.

As depicted in Chart 1 Salivary gland neoplastic lesions, tumors were presented over a wide range. The mean age for benign tumor was 43.39 years, malignant tumor was 49.95 years. In this study the youngest patient was 1 year and the eldest was 71 years of age.

![Chart 2](chart2)

Chart 2: Graph showing male and female distribution according to age.

Over all female preponderance was observed with ratio of 1:6. Among the benign lesions ratio observed was 1:1.5. M:F ratio in malignant lesion observed was 1:1.6 (Figure 1).

Most common site of benign and malignant salivary gland tumor is parotid with 38 and 15 cases respectively. Second most common site for benign lesion was submandibular gland with 6 cases, but in case of malignant lesion it was minor salivary gland with 7 cases (Chart 3).
Chart 3: Showing site distribution of benign and malignant salivary gland lesion

Fig. 1: Microphotograph of PA showing ductal structures surrounded by chondromyxoid stroma with, inset Alcian blue stain shows positive chondromyxoid areas (H&E, 40x and AB, 40x)

Fig. 2: Mucoepidermoid Carcinoma: Microphotograph showing three types of cells: squamous cells, intermediate cells and mucin producing cells. Inset perineural invasion (H&E, 40x)

Fig. 3: Mucoepidermoid Carcinoma: Microphotograph showing cyst lining with numerous mucous cells containing mucin pools and is PAS positive (PAS, 10x)

Fig. 4: Mucoepidermoid Carcinoma: Microphotograph showing mucicarmine positivity (MC 10x)

Fig. 5: Acinic cell carcinoma: Microphotograph showing large polygonal cells with basophilic granular cytoplasm, round, nuclei. Inset acinar cells are PAS positive (H&E, 40x and PAS 40x)
Fig. 6: Adenoid cystic carcinoma: Microphotograph showing basaloid cells arranged in tubules and cribriform pattern with cyst like spaces. Inset shows PAS positive material (H&E, 10x and PAS 40x)

| Table 1: Percentile distribution of benign and malignant Salivary gland lesion |
|-----------------------------|----------------|----------------|
| **Lesion**                   | **Male** | **Female** | **Percentage** |
| Benign                      |          |            |                |
| 1. Pleomorphic adenoma      | 13       | 21         | 48.57          |
| 2. Warthin’s tumour         | 03       | 02         | 7.14           |
| 3. Basal cell adenoma       | 01       | 02         | 4.28           |
| 4. Myoepithelioma           | 01       | 00         | 1.43           |
| 5. Oncocytoma               | 01       | 00         | 1.43           |
| 6. Hemangiomota             | 00       | 01         | 1.43           |
| 7. Salivolipomata           | 00       | 01         | 1.43           |
| Malignant                   |          |            |                |
| 1. Mucoepidermoid carcinoma | 04       | 08         | 17.14          |
| 2. Adenocystic carcinoma    | 02       | 02         | 5.71           |
| 3. Acinic cell carcinoma    | 01       | 02         | 4.28           |
| 4. Epithelial myoepithelial carcinoma | 00       | 01         | 1.43          |
| 5. Polymorphous adenocarcinoma | 00       | 01         | 1.43          |
| 6. Squamous cell carcinoma  | 01       | 00         | 1.43           |
| 7. Salivoblastoma           | 00       | 01         | 1.43           |
| 8. Lymphoma                 | 01       | 00         | 1.43           |

4. Discussion

Present study frequency of occurrence of benign tumors were more common when compared to malignant tumors similar results were noted in studies done by Krishnaraj Subhashraj, Vargas et al., Amin et al., Ito et al. and Bobati et al. The peak age incidence was in the 4th decade for both benign and malignant lesions. The mean age of benign tumor was 43yrs and for malignant tumor was 45yrs the present study correlates with Krishnaraj Subharris, Bobati et al. Satko et al. had slight higher average age of presentation.

There was female preponderance in both benign and malignant tumors, similar to other studies. However Ahmed et al. have observed a male preponderance and Bobati et al showed equal male female ratio in malignant lesions. Parotid was commonest site was seen in present study and correlated with other studies. Second most common site in our study is minor salivary gland similar to the studies done by Ito et al. Krishnaraj Subharris. Other studies done by Thomas et al., Ahmed et al. showed submandibular gland as second most common site. Thomas et al., Krishnaraj Subhashraj showed least cases in sublingual gland, present study had no cases in sublingual gland similar to Ito et al and Ahmed et al.

The PAS stain showed a strong reaction with the mucinous material in the tubules and myxoid arrears. Alcian blue stain was positive for chondromyxoid areas in Pleomorphic Adenoma. These result were similar to the studies done by Naag et al. and Azzopardi and Smith. The mucous cells and lumen of MEC showed positivity to MC PAS and AB indicating presence both sulphomucins and sialomucins similar results were observed by naag et al. One rare case was encountered in the study which was clear cell variant of MEC with positive to only PAS stain similar to results was made by Ogawa et al. AdCC showed positive for PAS and AB similar result was obtained by naag et al. While ACC showed PAS positive granules were seen in the cytoplasm of the tumor cells.

5. Conclusion

Parotid gland is the most frequently involved gland by salivary gland tumors. Most commonly presented in middle to older age group. Salivary gland tumors both benign and malignant are more frequent in females. Pleomorphic adenoma is most common salivary gland tumor Mucoepidermoid carcinoma is the most common malignant salivary gland tumor Very less literature is available on the mucin histochemistry of salivary gland tumors. Mucin stain acts as an adjunct to the routine H and E staining. Histopathological examination is gold standard method for diagnosis, predicting prognosis of malignant neoplasms of salivary gland.

6. Conflict of Interest

The authors declare that there are no conflicts of interest in this paper.

7. Source of Funding

None.

References

1. Sood S, Mcgurk M, Vaz F. Management of salivary gland tumours: United Kingdom national multidisciplinary guidelines. J Laryngol Otol. 2016;130(82):142–9.
2. Bobati SS, Patil BV, Dombale VD. Histopathological study of salivary gland tumors. *J Oral Maxillofac Pathol*. 2017;21(1):46–50. [doi:10.4103/0974-410X.243760](https://doi.org/10.4103/0974-410X.243760)

3. Tian Z, Li L, Wang L, Hu Y, Li J. Salivary gland neoplasms in oral and maxillofacial regions: a 23-year retrospective study of 6982 cases in an eastern Chinese population. *Int J Oral Maxillofac Surg*. 2010;39(3):235–42. [doi:10.1016/j.ijom.2009.10.016](https://doi.org/10.1016/j.ijom.2009.10.016)

4. Sun G, Yang X, Tang E, Wen J, Lu M, Hu Q, et al. The treatment of sublingual gland tumours. *Int J Oral Maxillofac Surg*. 2010;39(9):863–8.

5. Sardar MA, Guvur SM, Hazarey VK. A demographic study of salivary gland tumors. *SRM J Res Dent Sci*. 2018;9(2):67–73.

6. Naag SU, Adi RP. Histochemical study of salivary mucins in normal and neoplastic salivary glands. *J Clin Diagn Res*. 2010;4(6):3450–8.

7. William RP, Warwick R. Gray’s anatomy - The anatomical basis of clinical practice, 14th Edn. Churchill Livingstone, Elsevier; 2008.

8. Karambelkar RR, Shewale AD, Karambelkar RA, Umarji BN. Histochemical study of mucosubstances of normal human parotid salivary gland. *J Evol Med Dent Sci*. 2014;3(58):13079–855.

9. Parsons JT, Mendenhall WM, Stringer SP, Cassisi NJ, Million RR. Management of minor salivary gland carcinomas. *Int J Radiat Oncol Biol Phys*. 1996;35(3):443–54.

10. Subhashraj K. Salivary gland tumors: a single institution experience in India. *Br J Oral Maxillofac Surg*. 2008;46(8):635–8.

11. Vargas PA, Gerhard R, Filho J, Castro IV. Salivary gland tumors in a Brazilian population: A retrospective study of 124 cases. *Rev Hosp Clin Fac Med Sao Paulo*. 2002;57(6):271–6.

12. Amin NS, Shah SA, Prajapati SG, Goswami HM. Histomorphological spectrum of salivary gland tumors in a tertiary care hospital–A retrospective study. *Int J Med Sci Public Health*. 2017;6(2):299–303.

13. Ito FA, Ito PA, Vargas O, Lopes MAD. Salivary gland tumors in a Brazilian population: a retrospective study of 496 cases. *Int J Oral Maxillofac Surg*. 2005;34(5):533–6.

14. Satko I, Stanko P, Longauerová. Salivary gland tumors treated in the stomatological clinics in Bratislava. *Cranio-Maxillofac Surg*. 2000;28(1):56–61.

15. Ahmad S, Lateef M, Ahmad R. clinicopathological study of Primary Salivary Gland Tumors in Kashmir. *JK Practitioner*. 2002;9(4):231–3.

16. Thomas KM, Huttmsr. Borgenstein salivary gland tumors in Malawi. *Cancer*. 1980;46(10):2328–34. [doi:10.1002/1097-0142(19801015)46:10<2328::aid-cncr2820461036>3.0.co;2-s](https://doi.org/10.1002/1097-0142(19801015)46:10<2328::aid-cncr2820461036>3.0.co;2-s)

17. Azzopardi JG, Smith OD. Salivary gland tumours and their mucins. *J Pathol Bacteriol*. 1959;77(1):131–40. [doi:10.1002/path.1700770114](https://doi.org/10.1002/path.1700770114)

18. Ogawa I, Nikai H, Takata T, Yasui R. Clear-cell variant of mucoepidermoid carcinoma: report of a case with immunohistochemical and ultrastructural observations. *J Oral Maxillofac Surg*. 1992;50(8):906–10.

Author biography

**Faeeza Begum**, Post Graduate

**Shaista Choudhary**, Associate Professor

Cite this article: Begum F, Choudhary S. Morphological spectrum of salivary gland tumors with special reference to mucin stains. *IP J Diagn Pathol Oncol* 2021;6(4):267–271.